Compound ID | 1736
Synonym(s): ETI-204
Class: Antibody (monoclonal antibody [mAb])
Spectrum of activity: | Gram-positive |
Details of activity: | Active against B. anthracis |
Description: | Combination treatment for Inhalational anthrax caused by Bacillus anthracis |
Institute where first reported: | Elusys Therapeutics Inc |
Year first mentioned: | 2005 |
Highest developmental phase: | Approved by FDA in 2016 |
Development status: | Approved |
External links: | |
Guide to Pharmacology: | obiltoxaximab |
Citations: |
|